478 related articles for article (PubMed ID: 21437832)
21. [New drug treatment possibilities in castration resistant prostate carcinoma].
Meisel A; Stenner F
Praxis (Bern 1994); 2012 Sep; 101(18):1143-9; quiz 1150-1. PubMed ID: 22945814
[No Abstract] [Full Text] [Related]
22. New agents in the arsenal to fight castrate-resistant prostate cancer.
Ezzell EE; Chang KS; George BJ
Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
[TBL] [Abstract][Full Text] [Related]
23. Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC; Smaletz O; Herchenhorn D
Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
[TBL] [Abstract][Full Text] [Related]
24. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
Basset V; Flamand V; Crouzet S; Ploussard G
Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
[TBL] [Abstract][Full Text] [Related]
25. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
[TBL] [Abstract][Full Text] [Related]
26. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
27. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Mezynski J; Pezaro C; Bianchini D; Zivi A; Sandhu S; Thompson E; Hunt J; Sheridan E; Baikady B; Sarvadikar A; Maier G; Reid AHM; Mulick Cassidy A; Olmos D; Attard G; de Bono J
Ann Oncol; 2012 Nov; 23(11):2943-2947. PubMed ID: 22771826
[TBL] [Abstract][Full Text] [Related]
28. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
29. [New drugs in metastatic castration-resistant prostate cancer].
Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
[TBL] [Abstract][Full Text] [Related]
30. Progress in the treatment of advanced prostate cancer.
Sternberg CN; Petrylak DP; Madan RA; Parker C
Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
[TBL] [Abstract][Full Text] [Related]
31. Systemic therapeutic strategies for prostate cancer.
Nelson WG
Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
[No Abstract] [Full Text] [Related]
32. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
33. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
34. Novel concepts in androgen receptor blockade.
Hsieh AC; Ryan CJ
Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
[TBL] [Abstract][Full Text] [Related]
35. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
37. Abiraterone and increased survival in metastatic prostate cancer.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
[No Abstract] [Full Text] [Related]
38. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
39. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
40. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Ang JE; Olmos D; de Bono JS
Br J Cancer; 2009 Mar; 100(5):671-5. PubMed ID: 19223900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
